Current Treatment Options in Gastroenterology

, Volume 12, Issue 2, pp 211–228

Update on Recently Approved Treatments for Hepatitis C

  • Daniel Chao
  • Gregory J. Botwin
  • Timothy R. Morgan
Liver (J Bajaj, Section Editor)

DOI: 10.1007/s11938-014-0013-z

Cite this article as:
Chao, D., Botwin, G.J. & Morgan, T.R. Curr Treat Options Gastro (2014) 12: 211. doi:10.1007/s11938-014-0013-z

Opinion statement

Chronic hepatitis C virus (HCV) infection affects millions of individuals and is a significant cause of chronic liver disease and cirrhosis. Early treatment regimens relied on an immune-mediated response caused by interferon and only recently have medications acting directly on viral structures been discovered. In December 2013, two new medications, sofosbuvir and simeprevir, were approved by the US Food and Drug Administration (FDA) for treatment of chronic hepatitis C. This article reviews the approved treatment protocols for these two new medications and the clinical trials that fueled their development.

Keywords

Hepatitis C treatmentSofosbuvirSimeprevir

Abbreviations

BOC

Boceprevir

FDA

US Food and Drug Administration

GT

Genotype

HCV

Hepatitis C virus

IFN

Interferon

NI

Nucleos(t)ide inhibitor

NNI

Non-nucleos(t)ide inhibitor

NS

Non-structural

PegIFN

Pegylated interferon

PI

Protease inhibitor

RBV

Ribavirin

SMV

Simeprevir

SOF

Sofosbuvir

SVR

Sustained virologic response

TPV

Telaprevir

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2014

Authors and Affiliations

  • Daniel Chao
    • 1
    • 2
  • Gregory J. Botwin
    • 1
  • Timothy R. Morgan
    • 1
    • 2
  1. 1.Gastroenterology SectionVA Long Beach Healthcare System-11Long BeachUSA
  2. 2.Division of GastroenterologyUniversity of CaliforniaIrvineUSA